Daniel Bottomly
Overview
Explore the profile of Daniel Bottomly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barnes E, Eide C, Kaempf A, Bottomly D, Romine K, Wilmot B, et al.
Br J Haematol
. 2022 Oct;
200(3):323-328.
PMID: 36264026
Drug resistance in chronic myeloid leukaemia (CML) may occur via mutations in the causative BCR::ABL1 fusion or BCR::ABL1-independent mechanisms. We analysed 48 patients with BCR::ABL1-independent resistance for the presence of...
12.
Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K, et al.
Cancer Cell
. 2022 Jul;
40(8):850-864.e9.
PMID: 35868306
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large...
13.
Rice W, Howell S, Zhang H, Rastgoo N, Local A, Kurtz S, et al.
Mol Cancer Ther
. 2022 May;
21(7):1125-1135.
PMID: 35499387
Luxeptinib (CG-806) simultaneously targets FLT3 and select other kinase pathways operative in myeloid malignancies. We investigated the range of kinases it inhibits, its cytotoxicity landscape ex vivo with acute myeloid...
14.
Vigoda M, Mathieson C, Evans N, Hale C, Jennings J, Lucero O, et al.
Cancer Biol Ther
. 2022 Mar;
23(1):310-318.
PMID: 35343367
In this study, we report a differential response of mitogen-activated protein kinase-kinase (MEK) inhibitor trametinib in 20 head and neck squamous cell carcinoma (HNSCC) patients' tumor-derived cell cultures. Relatively sensitive...
15.
Thieme E, Liu T, Bruss N, Roleder C, Lam V, Wang X, et al.
Cell Death Dis
. 2022 Mar;
13(3):246.
PMID: 35296646
Aberrant B-cell receptor (BCR) signaling is a key driver in lymphoid malignancies. Bruton tyrosine kinase (BTK) inhibitors that disrupt BCR signaling have received regulatory approvals in therapy of mantle cell...
16.
Kurtz S, Eide C, Kaempf A, Long N, Bottomly D, Nikolova O, et al.
Blood Adv
. 2022 Jan;
6(10):3062-3067.
PMID: 35078224
Using ex vivo drug screening of primary patient specimens, we identified the combination of the p38 MAPK inhibitor doramapimod (DORA) with the BCL2 inhibitor venetoclax (VEN) as demonstrating broad, enhanced...
17.
Romine K, Nechiporuk T, Bottomly D, Jeng S, McWeeney S, Kaempf A, et al.
Blood Cancer Discov
. 2021 Sep;
2(5):518-531.
PMID: 34568834
To understand mechanisms of response to BET inhibitors (BETi), we mined the Beat AML functional genomic dataset and performed genome-wide CRISPR screens on BETi- sensitive and BETi- resistant AML cells....
18.
Yang F, Long N, Anekpuritanang T, Bottomly D, Savage J, Lee T, et al.
Blood
. 2021 Sep;
139(8):1208-1221.
PMID: 34482403
Inherited predisposition to myeloid malignancies is more common than previously appreciated. We analyzed the whole-exome sequencing data of paired leukemia and skin biopsy samples from 391 adult patients from the...
19.
Yenerall P, Kollipara R, Avila K, Peyton M, Eide C, Bottomly D, et al.
Cancer Res
. 2021 Jul;
81(18):4685-4695.
PMID: 34301758
Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). Here we...
20.
Joshi S, Nechiporuk T, Bottomly D, Piehowski P, Reisz J, Pittsenbarger J, et al.
Cancer Cell
. 2021 Jun;
39(7):999-1014.e8.
PMID: 34171263
Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute myeloid leukemia (AML). Early resistance is mediated by the bone marrow microenvironment, which protects residual leukemia cells. Over...